Assertio Therapeutics appoints Dr David Wheadon to its Board of Directors

– USA, IL –  Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that Dr. David Wheadon has been appointed to its Board of Directors. Dr. Wheadon is a former senior executive of AstraZeneca plc.

“David is a globally recognized leader in healthcare and we are thrilled to have him join our Board of Directors,” said Arthur Higgins, President and CEO of Assertio. “David’s perspectives, both as a physician and as an executive with significant and broad industry expertise, will add further depth and breadth to our Board.”

About Dr David Wheadon

Dr. Wheadon is a former senior executive of AstraZeneca plc, having recently retired as Senior Vice President, Global Regulatory Affairs, Patient Safety and Quality Assurance. Dr. Wheadon has held many leadership roles in the healthcare sector, including Executive Vice President, Research and Advocacy at the Juvenile Diabetes Research Foundation; Senior Vice President, Scientific and Regulatory Affairs at PhRMA; Senior Vice President of Global Pharmaceutical Regulatory and Medical Sciences at Abbott Laboratories; Senior Vice President of U.S. Regulatory Affairs at GlaxoSmithKline Pharmaceuticals; Vice President and Director CNS/GI Clinical Research at SmithKline Beecham Pharmaceuticals; and Clinical Research Physician at Eli Lilly and Company. Dr. Wheadon has been integral to the successful development and approval of several important drugs for central nervous system diseases, diabetes, gastrointestinal disorders and diseases in other therapeutic areas.

“I am excited to serve on Assertio’s Board and contribute to its ongoing transformation into a leading diversified biopharmaceutical company,” said Dr. Wheadon.

Dr. Wheadon holds an M.D. from Johns Hopkins University School of Medicine and an A.B. in Biology from Harvard University. He completed his postdoctoral training in Psychiatry at Tufts/New England Medical Center in Boston, Massachusetts.

About Assertio Therapeutics, Inc.

Assertio Therapeutics is committed to providing responsible solutions to advance patient care in the Company’s core areas of neurology, orphan and specialty medicines. Assertio currently markets three FDA-approved products and continues to identify, license and develop new products that offer enhanced options for patients that may be underserved by existing therapies.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>